Arthritis News and Research

Latest Arthritis News and Research

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Hospital for Special Surgery, (HSS), a world leader in orthopedics and rheumatology, today announced its support of the Arthritis Foundation and Ad Council newly launched campaign, "Moving is the Best Medicine," to raise awareness of osteoarthritis, increase public health education and support breakthrough research.

5 Feb 2010

Blood cytokine levels may help in predicting arthritic rheumatism

Levels of inflammatory proteins, so-called cytokines, are elevated in the blood even before the onset of arthritic rheumatism. This means that such blood samples could be used to predict the development of the disease and thereby make it possible to prevent the pathological process, according to an article by Umeå researcher Solbritt Rantapää-Dahlqvist and her associates in the journal Arthritis and Rheumatism.

4 Feb 2010

GTRI researchers design arthritis simulation gloves to meet the needs of consumers with functional limitations

As the U.S. population ages, manufacturers of consumer goods are realizing that many customers may not be as nimble-fingered or sharp-sighted as they once were.

4 Feb 2010

Ontario's doctors urge patients to make simple lifestyle changes for better health

The number of patients living with chronic disease in Ontario is on the rise, finds a new report by the Ontario Medical Association (OMA). The study reveals that between 1995-2005, the number of patients with diabetes has increased over 50% and more concerning is that the number of patients with diabetes aged 19 and younger has gone up by 20%.

4 Feb 2010

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.

3 Feb 2010

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for Assessing Metabolic Substrate Utilization” to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population.

2 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Isogenica, Phylogica partner in Phylomer peptide development

Isogenica Ltd today announced that it has entered into an agreement with Australian based biopharmaceutical company Phylogica to use Isogenica’s CIS display technology to optimize the performance of three of Phylogica’s lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases, such as Rheumatoid Arthritis and Inflammatory Bowel Disease.

2 Feb 2010

New biomarker may predict treatment outcomes in RA patients

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.

30 Jan 2010

Arthritis pain relief drug ALEVE now available OTC in British Columbia

This winter, British Columbians may be inspired to increase their activity level and take part in some favourite winter pastimes. For those who have joint and arthritis pain, getting back to doing the activities they love may be more of a challenge. ALEVE(R) is the first over-the-counter naproxen sodium tablet, and is now available province-wide. With just one pill, ALEVE(R) offers convenient access to pain relief for up to 12 hours.

29 Jan 2010

Nontoxic drug halts and reverses rheumatoid arthritis

A researcher from Northwestern University Feinberg School of Medicine has invented a novel way to halt and even reverse rheumatoid arthritis. He developed an imitation of a suicide molecule that floats undetected into overactive immune cells responsible for the disease.

29 Jan 2010

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany.

29 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

28 Jan 2010

Automated measurements more reliable in moderate cases of knee degeneration

Scientists have automated the measurement of a vital part of the knee in images with a computer program that performs much faster and just as reliably as humans who interpret the same images.

28 Jan 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.

28 Jan 2010

Study finds RA workers have similar keyboarding speed compared to non-impaired individuals

A recent study by researchers from the University of Pittsburgh found that workers with rheumatoid arthritis (RA) were comparable to non-impaired individuals in keyboarding speed. Individuals who were trained in touch typing demonstrated faster typing speeds than those using a visually-guided ("hunt and peck") method, regardless of impairment.

28 Jan 2010

Braces and supports can help prevent injury while gardening

Women risk any number of strains, sprains, and injuries while working in their gardens, but by using braces designed specifically for women’s bodies such as the ones made by Wellgate for Women, women are able to help reduce their pain and support their joints while still enjoying all the peace and relaxation that a garden brings.

28 Jan 2010

Arthritis News and Research

Latest Arthritis News and Research

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Blood cytokine levels may help in predicting arthritic rheumatism

GTRI researchers design arthritis simulation gloves to meet the needs of consumers with functional limitations

Ontario's doctors urge patients to make simple lifestyle changes for better health

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Isogenica, Phylogica partner in Phylomer peptide development

New biomarker may predict treatment outcomes in RA patients

Arthritis pain relief drug ALEVE now available OTC in British Columbia

Nontoxic drug halts and reverses rheumatoid arthritis

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Celgene reports total revenue of $758M for fourth-quarter of 2009

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Automated measurements more reliable in moderate cases of knee degeneration

Pfizer's new pipeline shows growth and diversity in research and development

Study finds RA workers have similar keyboarding speed compared to non-impaired individuals

Braces and supports can help prevent injury while gardening

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Arthritis News and Research

Latest Arthritis News and Research

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in